GE acquires Biosafe Group SA

Acquisition further develops integrated cell therapy and regenerative medicine offering to enable development and patient access to innovative life-saving therapies


Financial details of the transaction were not disclosed.

GE Healthcare has acquired Biosafe Group SA, a supplier of integrated cell bioprocessing systems for the rapidly growing cell therapy and regenerative medicine industry for an undisclosed sum.

The acquisition of Biosafe expands GE Healthcare's end-to-end ecosystem of products, solutions and services for our cell therapy customers, and expands GE's technology reach to a number of new cell and therapy types.

Biosafe, headquartered in the Lake Geneva region in Switzerland, with a global presence, has a 20 year track-record in automated cell processing and is a recognized leader in the field with reliable applications in bioprocessing, regenerative medicine and stem cell banking.

Its proprietary products offer significant advantages over conventional processing tools, with closed fluid pathways, built-in traceability and single-use consumables. The strong strategic fit and complementary business models of GE Healthcare's Life Sciences business and Biosafe combined with expanded capabilities in product development and commercial reach, will offer significant customer and ultimately patient benefits.

Kieran Murphy, CEO Life Sciences, GE Healthcare said: "GE is building a world-class set of tools, technologies and services for cell and gene therapy and Biosafe's expertise and innovative systems will strongly enhance our customer offering. GE and Biosafe share a vision of an integrated approach to helping customers optimize every stage of their process to reduce production risks dramatically and increase access to these remarkable new medicines."


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email